-
2
-
-
59349103787
-
The history of multiple sclerosis: The changing frame of the disease over the centuries
-
Murray TJ. The history of multiple sclerosis: the changing frame of the disease over the centuries. J. Neuro. Sci. 277(Suppl. 1), S3-S8 (2009).
-
(2009)
J. Neuro. Sci.
, vol.277
, Issue.SUPPL. 1
-
-
Murray, T.J.1
-
3
-
-
5144235394
-
Autoimmune concepts of MS as a basis for selective immunotherapy: From the pipe dreams to therapeutic pipelines
-
Hohlfeld R, Wekerle H. Autoimmune concepts of MS as a basis for selective immunotherapy: from the pipe dreams to therapeutic pipelines. Proc. Natl Acad. Sci. USA 101, 14599-14606 (2004).
-
(2004)
Proc. Natl Acad. Sci. USA
, vol.101
, pp. 14599-14606
-
-
Hohlfeld, R.1
Wekerle, H.2
-
4
-
-
53049085062
-
Mechanisms of Infammation induced tissue injury in multiple sclerosis
-
Lassmann H. Mechanisms of Infammation induced tissue injury in multiple sclerosis. J. Neuro. Sci. 274, 45-47 (2008).
-
(2008)
J. Neuro. Sci.
, vol.274
, pp. 45-47
-
-
Lassmann, H.1
-
5
-
-
46749151850
-
The immunology of multiple sclerosis: Disease mechanisms and therapeutic targets
-
Holmoy T. The immunology of multiple sclerosis: disease mechanisms and therapeutic targets. Minerva Med. 99, 119-140 (2008).
-
(2008)
Minerva Med.
, vol.99
, pp. 119-140
-
-
Holmoy, T.1
-
6
-
-
33645376448
-
Immunopathogenesis and immunotherapy of multiple sclerosis
-
Hemmer B, Nessler S, Zhou D. Kieseier B, Hartung HP. Immunopathogenesis and immunotherapy of multiple sclerosis. Nat. Clin. Pract. 2(4), 201-211 (2006).
-
(2006)
Nat. Clin. Pract.
, vol.2
, Issue.4
, pp. 201-211
-
-
Hemmer, B.1
Nessler, S.2
Zhou, D.3
Kieseier, B.4
Hartung, H.P.5
-
7
-
-
66549130329
-
The relation between infammation and neurodegeneration in multiple sclerosis brains
-
Frischer JM, Bramow S, Dal-Bianco A et al. The relation between infammation and neurodegeneration in multiple sclerosis brains. Brain 132, 1175-1189 (2009).
-
(2009)
Brain
, vol.132
, pp. 1175-1189
-
-
Frischer, J.M.1
Bramow, S.2
Dal-Bianco, A.3
-
9
-
-
48249139449
-
Multiple sclerosis: An immune or neurodegenerative disease
-
Trapp BD, Nave KA. Multiple sclerosis: an immune or neurodegenerative disease. Ann. Rev. Neurosci. 31, 247-269 (2008).
-
(2008)
Ann. Rev. Neurosci.
, vol.31
, pp. 247-269
-
-
Trapp, B.D.1
Nave, K.A.2
-
10
-
-
80755138257
-
Evidence for primary neurodegeneration in MS
-
Bruck W. Evidence for primary neurodegeneration in MS. Mult. Scler. (Suppl. 1), S9, 13 (2008).
-
(2008)
Mult. Scler. (Suppl. 1)
, vol.S9
, pp. 13
-
-
Bruck, W.1
-
11
-
-
48849116689
-
Grey matter pathology in multiple sclerosis
-
Geurts JJ, Barkhof F. Grey matter pathology in multiple sclerosis. Lancet Neurol. 7(9), 841-851 (2008).
-
(2008)
Lancet Neurol.
, vol.7
, Issue.9
, pp. 841-851
-
-
Geurts, J.J.1
Barkhof, F.2
-
12
-
-
77955659717
-
Neurodegeneration in autoimmune CNS infammation
-
DOI:10.1016/j.expneurol.2009.11.019 (Epub ahead of print)
-
Herz J, Zipp F, Siffrin V. Neurodegeneration in autoimmune CNS infammation. Exper. Neurol. DOI: 10.1016/j.expneurol.2009.11.019 (2009) (Epub ahead of print).
-
(2009)
Exper. Neurol.
-
-
Herz, J.1
Zipp, F.2
Siffrin, V.3
-
13
-
-
0000185990
-
Recombinant b interferon treatment of relapsing-remitting multiple sclerosis pilot study results
-
Johnson KP, Knobler RL, Greenstein JL et al. Recombinant b interferon treatment of relapsing-remitting multiple sclerosis pilot study results. Neurology 40(Suppl. 1), 261 (1990).
-
(1990)
Neurology
, vol.40
, Issue.SUPPL. 1
, pp. 261
-
-
Johnson, K.P.1
Knobler, R.L.2
Greenstein, J.L.3
-
14
-
-
0008678962
-
Intramuscular interferon b-1a for disease progression in relapsing multiple sclerosis
-
The Multiple Sclerosis Collaboration Group (MSCRG)
-
Jacobs LD, Cookfair DL, Rudick RA et al. Intramuscular interferon b-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaboration Group (MSCRG). Ann. Neurol. 39, 285-294 (1996)
-
(1996)
Ann. Neurol.
, vol.39
, pp. 285-294
-
-
Jacobs, L.D.1
Cookfair, D.L.2
Rudick, R.A.3
-
15
-
-
0345601517
-
Randomized, double blind, placebo controlled study of Interferon b-1a in relapsing-remitting multiple sclerosis: Chemical results
-
PRIM (Prevention of relapses and disability by interferon b-1a subsequently in multiple sclerosis) study group
-
PRIM (Prevention of relapses and disability by interferon b-1a subsequently in multiple sclerosis) study group. Randomized, double blind, placebo controlled study of Interferon b-1a in relapsing-remitting multiple sclerosis: chemical results. Lancet 352, 1498-1504 (1998).
-
(1998)
Lancet
, vol.352
, pp. 1498-1504
-
-
-
16
-
-
0015103005
-
Suppression of experimental allergic encephalomyelitis by a synthetic polypeptide
-
Teitelbaum D, Meshorer M, Hirshfeld T, Sela M, Arnon R. Suppression of experimental allergic encephalomyelitis by a synthetic polypeptide. Eur. J. Immunol. 1, 242-248 (1971).
-
(1971)
Eur. J. Immunol.
, vol.1
, pp. 242-248
-
-
Teitelbaum, D.1
Meshorer, M.2
Hirshfeld, T.3
Sela, M.4
Arnon, R.5
-
17
-
-
0029420295
-
Antagonsim of interferon b in interferon g: Inhibition of signal transduction in vitro and reduction of serum levels in multiple sclerosis patients
-
Revel M, Chebath J, Mangelus M et al. Antagonsim of interferon b in interferon g: inhibition of signal transduction in vitro and reduction of serum levels in multiple sclerosis patients. Mult. Scler. 1, S5-S11 (1995).
-
(1995)
Mult. Scler.
, vol.1
-
-
Revel, M.1
Chebath, J.2
Mangelus, M.3
-
19
-
-
34250159112
-
Interferon-b: Mechanism of action and dosing issues
-
Markowitz CE. Interferon-b: mechanism of action and dosing issues. Neurology 68, S8-S11 (2007).
-
(2007)
Neurology
, vol.68
-
-
Markowitz, C.E.1
-
20
-
-
10744225329
-
Clinical importance of neutralizing antibodies against interferon b in patients with relapsing-remitting multiple sclerosis
-
Sorensen PS, Ross C, Clemmesen KM et al. Clinical importance of neutralizing antibodies against interferon b in patients with relapsing-remitting multiple sclerosis. Lancet 362, 1184-11161 (2003).
-
(2003)
Lancet
, vol.362
, pp. 1184-11161
-
-
Sorensen, P.S.1
Ross, C.2
Clemmesen, K.M.3
-
21
-
-
34147161297
-
Neutralizing antibodies to interferon b: Assessment of their clinical and radiographic impact
-
An evidence report to the Therapeutics and Technology Assessment Subcomittee of the American Academy of Neurology
-
Goodin DS, Frohman EM, Hurwitz B et al Neutralizing antibodies to interferon b: assessment of their clinical and radiographic impact. An evidence report to the Therapeutics and Technology Assessment Subcomittee of the American Academy of Neurology. Neurology 68(13), 977-984 (2007).
-
(2007)
Neurology
, vol.68
, Issue.13
, pp. 977-984
-
-
Goodin, D.S.1
Frohman, E.M.2
Hurwitz, B.3
-
22
-
-
34447269090
-
The interferon b-1b 16-year long-term follow-up study: The fnal results
-
Ebers G. The interferon b-1b 16-year long-term follow-up study: the fnal results. Neurology 66, A32 (2006).
-
(2006)
Neurology
, vol.66
-
-
Ebers, G.1
-
23
-
-
0028340163
-
Direct binding of myelin basic protein and synthetic copolymer 1 class II major histocompatibility complex molecules on living antigen presenting cells-specifcity and promiscuity
-
Fridkis-Hareli M, Teitelbaum D, Gurevich E et al. Direct binding of myelin basic protein and synthetic copolymer 1 class II major histocompatibility complex molecules on living antigen presenting cells-specifcity and promiscuity. Proc. Natl Acad. Sci. USA 91, 4872-4876 (1994).
-
(1994)
Proc. Natl Acad. Sci. USA
, vol.91
, pp. 4872-4876
-
-
Fridkis-Hareli, M.1
Teitelbaum, D.2
Gurevich, E.3
-
24
-
-
34547699396
-
Type II monocytes modulate T cell-mediated central nervous system autoimmune disease
-
Weber MS, Prod'homme T, Youssef S et al. Type II monocytes modulate T cell-mediated central nervous system autoimmune disease. Nature Med. 13(8), 935-943 (2007).
-
(2007)
Nature Med.
, vol.13
, Issue.8
, pp. 935-943
-
-
Weber, M.S.1
Prod'Homme, T.2
Youssef, S.3
-
25
-
-
0030987548
-
Copolymer 1 induces T cells of the T helper type 2 that cross react with myelin basic protein and suppress experimental autoimmune encephalomyelitis
-
Aharoni R, Teitelbaum D, Sela M. Arnon R. Copolymer 1 induces T cells of the T helper type 2 that cross react with myelin basic protein and suppress experimental autoimmune encephalomyelitis. Proc. Natl Acad. Sci. USA 94, 10821-10826 (1997).
-
(1997)
Proc. Natl Acad. Sci. USA
, vol.94
, pp. 10821-10826
-
-
Aharoni, R.1
Teitelbaum, D.2
Sela, M.3
Arnon, R.4
-
26
-
-
0034691165
-
Multiple sclerosis comparison of copolymer-1 reactive T cell lines from treated and untreated subjects reveals cytokine shift from T helper 1 to T helper 2 cells
-
Neuhaus O, Farina C, Yassouridis A. Multiple sclerosis comparison of copolymer-1 reactive T cell lines from treated and untreated subjects reveals cytokine shift from T helper 1 to T helper 2 cells. Proc. Natl Acad. Sci. USA 97, 7452-7457 (2000).
-
(2000)
Proc. Natl Acad. Sci. USA
, vol.97
, pp. 7452-7457
-
-
Neuhaus, O.1
Farina, C.2
Yassouridis, A.3
-
27
-
-
0344198593
-
Glatiramer acetate specifc T-cells in the brain express TH2/3 cytokines and brain-derived neurotrophic factor in situ
-
Aharoni R, Kayhan B, Eilam R, Sela M, Arnon R. Glatiramer acetate specifc T-cells in the brain express TH2/3 cytokines and brain-derived neurotrophic factor in situ. Proc. Natl Acad. Sci. USA 100(24), 14157-14162 (2003).
-
(2003)
Proc. Natl Acad. Sci. USA
, vol.100
, Issue.24
, pp. 14157-14162
-
-
Aharoni, R.1
Kayhan, B.2
Eilam, R.3
Sela, M.4
Arnon, R.5
-
28
-
-
48349114325
-
Multiple sclerosis: Glatiramer acetate induces anti-infammatory T cells in the cerebrospinal fuid
-
Hestvik AL, Skorstad G, Price DA, Vartdal F, Holmoy T. Multiple sclerosis: glatiramer acetate induces anti-infammatory T cells in the cerebrospinal fuid. Mult. Scler. 14(6), 749-758 (2008).
-
(2008)
Mult. Scler.
, vol.14
, Issue.6
, pp. 749-758
-
-
Hestvik, A.L.1
Skorstad, G.2
Price, D.A.3
Vartdal, F.4
Holmoy, T.5
-
29
-
-
34548510355
-
+ regulatory T cells contribute to the therapeutic effects of glatiramer acetate in experimental autoimmune encephalomyelitis
-
+ regulatory T cells contribute to the therapeutic effects of glatiramer acetate in experimental autoimmune encephalomyelitis. Clin. Immunol. 125, 34-42 (2007).
-
(2007)
Clin. Immunol.
, vol.125
, pp. 34-42
-
-
Jee, Y.1
Piao, W.H.2
Liu, R.3
-
30
-
-
54449085895
-
Downregulation of IL-17 and IL-6 in the central nervous system by glatiramer acetate in experimental autoimmune encephalomyelitis
-
Begum-Haque S, Sharma, A, Kasper I et al. Downregulation of IL-17 and IL-6 in the central nervous system by glatiramer acetate in experimental autoimmune encephalomyelitis. J. Neuroimmunol. 204, 58-65 (2008).
-
(2008)
J. Neuroimmunol.
, vol.204
, pp. 58-65
-
-
Begum-Haque, S.1
Sharma, A.2
Kasper, I.3
-
31
-
-
77955658134
-
Glatiramer acetate reduces Th-17 infammation and induces regulatory T-cells in the CNS of mice with relapsing-remitting or chronic EAE
-
DOI:10.1016/j.jneuroim.2010.04.022 (Epub ahead of print)
-
Aharoni R, Eilam R, Stock A et al. Glatiramer acetate reduces Th-17 infammation and induces regulatory T-cells in the CNS of mice with relapsing-remitting or chronic EAE. J. Neuroimmunol. DOI: 10.1016/j.jneuroim. 2010.04.022 (2010) (Epub ahead of print).
-
(2010)
J. Neuroimmunol.
-
-
Aharoni, R.1
Eilam, R.2
Stock, A.3
-
32
-
-
77949885488
-
Continuous long-term immunomodulatory therapy in relapsing multiple sclerosis: Results from the 15-year analysis of the US prospective open-labeled study of glatiramer acetate
-
Ford C, Goodman AD, Johnson K et al. Continuous long-term immunomodulatory therapy in relapsing multiple sclerosis: results from the 15-year analysis of the US prospective open-labeled study of glatiramer acetate. Mult. Scler. 16(3), 342-350 (2010).
-
(2010)
Mult. Scler.
, vol.16
, Issue.3
, pp. 342-350
-
-
Ford, C.1
Goodman, A.D.2
Johnson, K.3
-
33
-
-
72649104547
-
Current therapeutic recommendations in multiple sclerosis
-
Berger T. Current therapeutic recommendations in multiple sclerosis. J. Neurol. Sci. 287(Suppl. 1), S37-S45 (2009).
-
(2009)
J. Neurol. Sci.
, vol.287
, Issue.SUPPL. 1
-
-
Berger, T.1
-
34
-
-
55749098474
-
Modern multiple sclerosis treatment-what is approved, what is on the horizon
-
Pilz G, Wipfer P, Ladurner G, Kraus J. Modern multiple sclerosis treatment-what is approved, what is on the horizon. Drug Discov. Today 13, 1013-1025 (2008).
-
(2008)
Drug Discov. Today
, vol.13
, pp. 1013-1025
-
-
Pilz, G.1
Wipfer, P.2
Ladurner, G.3
Kraus, J.4
-
36
-
-
0035091667
-
European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging measured disease activity and burden in patients with relapsing multiple sclerosis
-
European/Canadian Glatiramer Acetate Study Group
-
Comi G, Filippi M, Wolinsky JS. European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging measured disease activity and burden in patients with relapsing multiple sclerosis. European/Canadian Glatiramer Acetate Study Group. Ann. Neurol. 49(3), 290-297 (2001).
-
(2001)
Ann. Neurol.
, vol.49
, Issue.3
, pp. 290-297
-
-
Comi, G.1
Filippi, M.2
Wolinsky, J.S.3
-
37
-
-
22144447781
-
Interferon p in relapsing-remitting multiple sclerosis. An eight years experience in a specialist multiple sclerosis centre
-
Rio J, Tintoré M, Nos C, Téllez N, Galán I, Montalban X. Interferon p in relapsing-remitting multiple sclerosis. An eight years experience in a specialist multiple sclerosis centre. J. Neurol. 252(7), 795-800 (2005).
-
(2005)
J. Neurol.
, vol.252
, Issue.7
, pp. 795-800
-
-
Rio, J.1
Tintoré, M.2
Nos, C.3
Téllez, N.4
Galán, I.5
Montalban, X.6
-
38
-
-
56349112817
-
Glatiramer acetate after mitoxantrone induction improves MRI markers of lesion volume and permanent tissue injury in MS
-
Arnold DL, Campagnolo D, Panitch H, et al. Glatiramer acetate after mitoxantrone induction improves MRI markers of lesion volume and permanent tissue injury in MS. J. Neurol. 255(10), 1473-1478 (2008).
-
(2008)
J. Neurol.
, vol.255
, Issue.10
, pp. 1473-1478
-
-
Arnold, D.L.1
Campagnolo, D.2
Panitch, H.3
-
39
-
-
18844365126
-
Multiple diagnosis and management of acute relapses
-
Leary SM, Porter B. Thompson A. Multiple diagnosis and management of acute relapses. Postgrad. Med. J. 81, 302-308 (2005).
-
(2005)
Postgrad. Med. J.
, vol.81
, pp. 302-308
-
-
Leary, S.M.1
Porter, B.2
Thompson, A.3
-
40
-
-
0025986898
-
Overview of azathioprine treatment in multiple sclerosis
-
Yudkin PL, Ellison GW, Ghezzi A et al. Overview of azathioprine treatment in multiple sclerosis. Lancet 338, 1051-1055 (1991).
-
(1991)
Lancet
, vol.338
, pp. 1051-1055
-
-
Yudkin, P.L.1
Ellison, G.W.2
Ghezzi, A.3
-
41
-
-
0022450390
-
Selective immunomodulation by the anti-neoplastic agent mitoxantrone, suppression of B lymphocyte function
-
Filder JM, Dejoy SQ, Gibbons JJ Jr. Selective immunomodulation by the anti-neoplastic agent mitoxantrone, suppression of B lymphocyte function. J. Immunol. 137(2), 727-732 (1986).
-
(1986)
J. Immunol.
, vol.137
, Issue.2
, pp. 727-732
-
-
Filder, J.M.1
Dejoy, S.Q.2
Gibbons Jr., J.J.3
-
42
-
-
0037153729
-
Mitoxantrone in progressive multiple sclerosis: A placebo-controlled, double-blind, randomised, multicentre trial
-
Hartung HP, Gonsette R, König N et al. Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomised, multicentre trial. Lancet 360, 2018-2025 (2002).
-
(2002)
Lancet
, vol.360
, pp. 2018-2025
-
-
Hartung, H.P.1
Gonsette, R.2
König, N.3
-
43
-
-
28244485979
-
Mitoxantrone in the treatment of multiple sclerosis
-
Morrissey SP, Le Page E, Edan G. Mitoxantrone in the treatment of multiple sclerosis. Int. MS J. 12, 74-87 (2005).
-
(2005)
Int. MS J.
, vol.12
, pp. 74-87
-
-
Morrissey, S.P.1
Le Page, E.2
Edan, G.3
-
44
-
-
40349096094
-
Combination therapies in multiple sclerosis
-
Gold R. Combination therapies in multiple sclerosis. J. Neurol. 255, 51-60 (2008).
-
(2008)
J. Neurol.
, vol.255
, pp. 51-60
-
-
Gold, R.1
-
45
-
-
17644398787
-
Anti-a4 integrin therapy for multiple sclerosis: Mechanism and rationale
-
Rice GP, Hartung HP, Calabresi PA. Anti-a4 integrin therapy for multiple sclerosis: mechanism and rationale. Neurology 64(8), 1336-1342 (2005).
-
(2005)
Neurology
, vol.64
, Issue.8
, pp. 1336-1342
-
-
Rice, G.P.1
Hartung, H.P.2
Calabresi, P.A.3
-
46
-
-
37149030961
-
Natalizumab: Targeting a4-integrins in multiple sclerosis
-
Engelhardt B, Kappos L. Natalizumab: targeting a4-integrins in multiple sclerosis. Neurodegener. Dis. 5(1), 16-22 (2008).
-
(2008)
Neurodegener. Dis.
, vol.5
, Issue.1
, pp. 16-22
-
-
Engelhardt, B.1
Kappos, L.2
-
47
-
-
77949279537
-
Natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: Lessons from 28 cases
-
Clifford DB, De Luca A, Simpson DM, Arendt G, Giovannoni G, Nath A. Natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: lessons from 28 cases. Lancet Neurol. 9(4), 438-446 (2010).
-
(2010)
Lancet Neurol.
, vol.9
, Issue.4
, pp. 438-446
-
-
Clifford, D.B.1
De Luca, A.2
Simpson, D.M.3
Arendt, G.4
Giovannoni, G.5
Nath, A.6
-
48
-
-
69249202564
-
The future of multiple sclerosis therapy
-
Kieseier B, Wiendl H, Hartung HP, Stuve O. The future of multiple sclerosis therapy. Pharmacol. Res. 60, 207-211 (2009).
-
(2009)
Pharmacol. Res.
, vol.60
, pp. 207-211
-
-
Kieseier, B.1
Wiendl, H.2
Hartung, H.P.3
Stuve, O.4
-
49
-
-
74049120922
-
New oral drugs for multiple sclerosis
-
Gasperini C, Ruggierir S. New oral drugs for multiple sclerosis. Neurol. Sci. 30(2), S170-S183 (2009).
-
(2009)
Neurol. Sci.
, vol.30
, Issue.2
-
-
Gasperini, C.1
Ruggierir, S.2
-
50
-
-
74249102004
-
Emerging multiple sclerosis oral therapies
-
Rammohan K, Shoemaker J. Emerging multiple sclerosis oral therapies. Neurology 74, S47-S53 (2010).
-
(2010)
Neurology
, vol.74
-
-
Rammohan, K.1
Shoemaker, J.2
-
51
-
-
0037077308
-
The immune modulator FTY720 targets sphingosine 1-phosphate receptor
-
Brinkmann V, Davis MD, Heise CE et al. The immune modulator FTY720 targets sphingosine 1-phosphate receptor. J. Biol Chem. 277, 21453-21473 (2002).
-
(2002)
J. Biol Chem.
, vol.277
, pp. 21453-21473
-
-
Brinkmann, V.1
Davis, M.D.2
Heise, C.E.3
-
52
-
-
28044462458
-
FTY720, a new class of immunomodulator, inhibits lymphocyte egress from secondary lymphoid tissues and thymus by agonistic activity at sphingosine 1-phosphate receptor
-
Chiba K. FTY720, a new class of immunomodulator, inhibits lymphocyte egress from secondary lymphoid tissues and thymus by agonistic activity at sphingosine 1-phosphate receptor. Phamacol. Ther. 108, 308-319 (2005).
-
(2005)
Phamacol. Ther.
, vol.108
, pp. 308-319
-
-
Chiba, K.1
-
53
-
-
0036205659
-
First human trial of FTY720, a novel immunomodulator, in stable renal transplant patients
-
Budde K, Schomouder RL, Brunkhorst R et al. First human trial of FTY720, a novel immunomodulator, in stable renal transplant patients. J. Am. Soc. Neprol. 13, 1073-1083 (2002).
-
(2002)
J. Am. Soc. Neprol.
, vol.13
, pp. 1073-1083
-
-
Budde, K.1
Schomouder, R.L.2
Brunkhorst, R.3
-
54
-
-
3242683494
-
Sphingosine 1-phosphate receptor agonists attenuate relapsing-remitting experimental autoimmune encephalomyelitis in SJL mice
-
Webb M, Tham CS, Lin FF et al. Sphingosine 1-phosphate receptor agonists attenuate relapsing-remitting experimental autoimmune encephalomyelitis in SJL mice. J. Neuroimmunol. 153, 108-121 (2004).
-
(2004)
J. Neuroimmunol.
, vol.153
, pp. 108-121
-
-
Webb, M.1
Tham, C.S.2
Lin, F.F.3
-
55
-
-
76149140914
-
Oral fngolimod or intramuscular interferon for relapsing multiple sclerosis
-
Cohen JA, Barkof F, Comi G et al. Oral fngolimod or intramuscular interferon for relapsing multiple sclerosis. N. Engl. J. Med. 362(5), 402-415 (2010).
-
(2010)
N. Engl. J. Med.
, vol.362
, Issue.5
, pp. 402-415
-
-
Cohen, J.A.1
Barkof, F.2
Comi, G.3
-
56
-
-
76149093586
-
A placebo controlled trial of oral fngolimod in relapsing multiple sclerosis
-
Kappos L, Radue EW, O'Connor P et al. A placebo controlled trial of oral fngolimod in relapsing multiple sclerosis. N. Engl J. Med. 362(5), 387-401 (2010).
-
(2010)
N. Engl J. Med.
, vol.362
, Issue.5
, pp. 387-401
-
-
Kappos, L.1
Radue, E.W.2
O'Connor, P.3
-
57
-
-
0026799508
-
Cladribine (2-chlorodeoxyadenine)
-
Beutler E. Cladribine (2-chlorodeoxyadenine). Lancet 340, 952-956 (1992).
-
(1992)
Lancet
, vol.340
, pp. 952-956
-
-
Beutler, E.1
-
58
-
-
27944443692
-
Cladribine for multiple sclerosis: Review and current status
-
Sipe LC. Cladribine for multiple sclerosis: review and current status. Expert Rev. Neurother. 5, 721-727 (2005).
-
(2005)
Expert Rev. Neurother.
, vol.5
, pp. 721-727
-
-
Sipe, L.C.1
-
59
-
-
0029983154
-
The treatment of chronic progressive multiple sclerosis with cladribine
-
DOI 10.1073/pnas.93.4.1716
-
Beutler E, Sipe JC, Romine JS, Koziol JA, McMillan R, Zyroff J. The treatment of chronic progressive multiple sclerosis with cladribin. Proc. Natl Acad. Sci. USA 93(4), 1716-1720 (1996). (Pubitemid 26075191)
-
(1996)
Proceedings of the National Academy of Sciences of the United States of America
, vol.93
, Issue.4
, pp. 1716-1720
-
-
Beutler, E.1
Sipe, J.C.2
Romine, J.S.3
Koziol, J.A.4
Mcmillan, R.5
Zyroff, J.6
-
60
-
-
33749636174
-
Cladribine: An investigational immunomodulatory agent for multiple sclerosis
-
Brousil JA, Roberts RJ, Schlein AL. Cladribine: an investigational immunomodulatory agent for multiple sclerosis. Ann. Pharmacother. 40(10), 1814-1821 (2006).
-
(2006)
Ann. Pharmacother.
, vol.40
, Issue.10
, pp. 1814-1821
-
-
Brousil, J.A.1
Roberts, R.J.2
Schlein, A.L.3
-
61
-
-
0034646216
-
Cladribine and progressive MS. Clinical and MRI outcomes of multicenter controlled trial
-
Rice GPA, Filippi M, Comi G. Cladribine and progressive MS. Clinical and MRI outcomes of multicenter controlled trial. Neurology 54(5), 1145-1155 (2000).
-
(2000)
Neurology
, vol.54
, Issue.5
, pp. 1145-1155
-
-
Gpa, R.1
Filippi, M.2
Comi, G.3
-
62
-
-
76149083915
-
A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis
-
Giovannoni G, Comi G, Cook S et al. A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis. N. Engl. J. Med. 362(5), 416-426 (2010).
-
(2010)
N. Engl. J. Med.
, vol.362
, Issue.5
, pp. 416-426
-
-
Giovannoni, G.1
Comi, G.2
Cook, S.3
-
63
-
-
27844528579
-
Lefunomid: Clinical effectiveness and mechanism of action
-
Nakajima A, Yamanaka H, Kamatani N. Lefunomid: clinical effectiveness and mechanism of action. Clin. Calcium 13(6), 771-775 (2003).
-
(2003)
Clin. Calcium
, vol.13
, Issue.6
, pp. 771-775
-
-
Nakajima, A.1
Yamanaka, H.2
Kamatani, N.3
-
64
-
-
0033557695
-
Immunosuppressive lefunomide metabolite (A77 1726) blocks TNF-dependent nuclear factor kB activation and gene expression
-
Manna SK, Aggarwal BB. Immunosuppressive lefunomide metabolite (A77 1726) blocks TNF-dependent nuclear factor kB activation and gene expression. J. Immunol. 162, 2095-2102 (1999).
-
(1999)
J. Immunol.
, vol.162
, pp. 2095-2102
-
-
Manna, S.K.1
Aggarwal, B.B.2
-
65
-
-
0034840913
-
Suppression of experimental autoimmune neuritis by lefunomide
-
Korn T, Toyka K, Hartung HP et al. Suppression of experimental autoimmune neuritis by lefunomide. Brain 124, 1791-1802 (2001).
-
(2001)
Brain
, vol.124
, pp. 1791-1802
-
-
Korn, T.1
Toyka, K.2
Hartung, H.P.3
-
66
-
-
62149096116
-
Terifunomide reduces behavioral, electrophysiological, and histopathological defcits in the Dark Agouti rat model of experimental autoimmune encephalomyelitis
-
Merrill JE, Hanak S, Pu SF et al. Terifunomide reduces behavioral, electrophysiological, and histopathological defcits in the Dark Agouti rat model of experimental autoimmune encephalomyelitis. J. Neurol. 256(1), 89-103 (2009).
-
(2009)
J. Neurol.
, vol.256
, Issue.1
, pp. 89-103
-
-
Merrill, J.E.1
Hanak, S.2
Pu, S.F.3
-
67
-
-
33645799680
-
A Phase II study of the safety and effcacy of terifunomide in multiple sclerosis with relapses
-
O'Connor PW, Li D, Freedman MS et al. A Phase II study of the safety and effcacy of terifunomide in multiple sclerosis with relapses. Neurology 66, 894-900 (2006).
-
(2006)
Neurology
, vol.66
, pp. 894-900
-
-
O'Connor, P.W.1
Li, D.2
Freedman, M.S.3
-
68
-
-
77949285625
-
Oral terifunomide or placebo added to interferon-b for 6 months in patients with relapsing multiple sclerosis: Safety and effcacy results
-
Presented at. Düsseldorf Germany September
-
Freedman M, Wolinsky JS, Byrnes WJ. Oral terifunomide or placebo added to interferon-b for 6 months in patients with relapsing multiple sclerosis: safety and effcacy results. Presented at: European Committee for Treatment and Research in Multiple Sclerosis Annual Meeting. Düsseldorf, Germany, September 2009.
-
(2009)
European Committee for Treatment and Research in Multiple Sclerosis Annual Meeting
-
-
Freedman, M.1
Wolinsky, J.S.2
Byrnes, W.J.3
-
69
-
-
11844304978
-
Dimethylfumarate for psoriasis: More than a dietary curiosity
-
Mrowietz U, Asadullan K. Dimethylfumarate for psoriasis: more than a dietary curiosity. Trends Mol. Med. 11(1), 43-48 (2005).
-
(2005)
Trends Mol. Med.
, vol.11
, Issue.1
, pp. 43-48
-
-
Mrowietz, U.1
Asadullan, K.2
-
70
-
-
0029846154
-
Selective stimulation of T helper 2 cytokine responses by the anti-psoriasis agent monomethylfumarate
-
De Jong R, Bezemer AC, Zomerdijk TP, van de Pouw-Kraan T, Ottenhoff TH, Nibbering PH. Selective stimulation of T helper 2 cytokine responses by the anti-psoriasis agent monomethylfumarate. Eur. J. Immunol. 26(9), 2067-2074 (1996).
-
(1996)
Eur. J. Immunol.
, vol.26
, Issue.9
, pp. 2067-2074
-
-
De Jong, R.1
Bezemer, A.C.2
Zomerdijk, T.P.3
Van De Pouw-Kraan, T.4
Ottenhoff, T.H.5
Nibbering, P.H.6
-
71
-
-
0345732760
-
Dimethylfumarate is a potent inducer of apoptosis in human T cells
-
Treumer F, Zhu K, Gläser R, Mrowietz U. Dimethylfumarate is a potent inducer of apoptosis in human T cells. J. Invest. Dermatol. 121(6), 1383-1388 (2003).
-
(2003)
J. Invest. Dermatol.
, vol.121
, Issue.6
, pp. 1383-1388
-
-
Treumer, F.1
Zhu, K.2
Gläser, R.3
Mrowietz, U.4
-
72
-
-
0031577292
-
An Nrf2/small Maf heterodimer mediates the induction of phase II detoxifying enzyme genes through antioxidant response elements
-
Itoh K, Chiba T, Takahashi S et al. An Nrf2/small Maf heterodimer mediates the induction of phase II detoxifying enzyme genes through antioxidant response elements. Biochem. Biophys. Res. Commun. 236(2), 313-322 (1997).
-
(1997)
Biochem. Biophys. Res. Commun.
, vol.236
, Issue.2
, pp. 313-322
-
-
Itoh, K.1
Chiba, T.2
Takahashi, S.3
-
73
-
-
51649088304
-
Activation of Nrf2 and modulation of disease progression in EAE model by BG00012 (dimethylfumarate) suggests a novel mechanism of action combining anti-infammatory and neuroprotective modulities
-
Lakashev M Zeng W, Goetz S et al. Activation of Nrf2 and modulation of disease progression in EAE model by BG00012 (dimethylfumarate) suggests a novel mechanism of action combining anti-infammatory and neuroprotective modulities. Mult. Scler. 13(2), 503 (2007).
-
(2007)
Mult. Scler.
, vol.13
, Issue.2
, pp. 503
-
-
Lakashev Zeng M, W.1
Goetz, S.2
-
74
-
-
54149116366
-
Effcacy and safety of oral fumarate in patients with relapsing-remitting multiple sclerosis: A multicentre, randomised, double-blind, placebo-controlled Phase IIb study
-
Kappos L, Gold R, Miller DH et al. Effcacy and safety of oral fumarate in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled Phase IIb study. Lancet 372, 1463-1472 (2008).
-
(2008)
Lancet
, vol.372
, pp. 1463-1472
-
-
Kappos, L.1
Gold, R.2
Miller, D.H.3
-
75
-
-
11144357311
-
Synthesis and biological evaluation of new 1,2-dihydro-4-hydroxy-2-oxo-3- quinolinecarboxamides for treatment of autoimmune disorders: Structure-activity relationship
-
Jönsson S, Andersson G, Fex T et al. Synthesis and biological evaluation of new 1,2-dihydro-4-hydroxy-2-oxo-3-quinolinecarboxamides for treatment of autoimmune disorders: structure-activity relationship. J. Med. Chem. 47(8), 2075-2088. (2004).
-
(2004)
J. Med. Chem.
, vol.47
, Issue.8
, pp. 2075-2088
-
-
Jönsson, S.1
Andersson, G.2
Fex, T.3
-
76
-
-
0036710356
-
The new orally active immunoregulator laquinimod (ABR-215062) effectively inhibits development and relapses of experimental autoimmune encephalomyelitis
-
Brunmark C, Runstrom A, Ohlsson L et al. The new orally active immunoregulator laquinimod (ABR-215062) effectively inhibits development and relapses of experimental autoimmune encephalomyelitis. J. Neuroimmunol. 130, 163-172 (2002).
-
(2002)
J. Neuroimmunol.
, vol.130
, pp. 163-172
-
-
Brunmark, C.1
Runstrom, A.2
Ohlsson, L.3
-
77
-
-
4744340401
-
Laquinimod (ABR-215062) suppresses the development of experimental autoimmune encephalomyelitis, modulates the Th1/Th2 balance and induces the Th3 cytokine TGF-b in Lewis rats
-
Yang JS, Xu LY, Xiao BG, Hedlund G, Link H. Laquinimod (ABR-215062) suppresses the development of experimental autoimmune encephalomyelitis, modulates the Th1/Th2 balance and induces the Th3 cytokine TGF-b in Lewis rats. J. Neuroimmunol. 156(1-2), 3-9 (2004).
-
(2004)
J. Neuroimmunol.
, vol.156
, Issue.1-2
, pp. 3-9
-
-
Yang, J.S.1
Xu, L.Y.2
Xiao, B.G.3
Hedlund, G.4
Link, H.5
-
78
-
-
15244353263
-
Treatment with laquinimod reduces development of active MRI lesions in relapsing MS
-
Polman C, Barkhof F, Sandberg-Wollheim M, Linde A, Nordle O, Nederman T. Treatment with laquinimod reduces development of active MRI lesions in relapsing MS. Neurology 64, 987-991 (2005).
-
(2005)
Neurology
, vol.64
, pp. 987-991
-
-
Polman, C.1
Barkhof, F.2
Sandberg-Wollheim, M.3
Linde, A.4
Nordle, O.5
Nederman, T.6
-
79
-
-
45249107267
-
Effect of laquinimod on MRI-monitored disease activity in patients with relapsing-remitting multiple sclerosis: A multicentre, randomised, double-blind, placebo-controlled Phase IIb study
-
Comi G, Pulizzi A, Rovaris M et al. Effect of laquinimod on MRI-monitored disease activity in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled Phase IIb study. Lancet 371, 2085-2092 (2008).
-
(2008)
Lancet
, vol.371
, pp. 2085-2092
-
-
Comi, G.1
Pulizzi, A.2
Rovaris, M.3
-
80
-
-
8844254741
-
The promise of minocycline in neurology
-
Yong V W, Wells J, Giuliani F, Casha S, Power C, Metz LM. The promise of minocycline in neurology. Lancet Neurol. 3(12), 744-751 (2004).
-
(2004)
Lancet Neurol.
, vol.3
, Issue.12
, pp. 744-751
-
-
Yong, V.W.1
Wells, J.2
Giuliani, F.3
Casha, S.4
Power, C.5
Metz, L.M.6
-
81
-
-
11144354138
-
Minocycline reduces gadolinium-enhancing magnetic resonance imaging lesions in multiple sclerosis
-
Metz LM, Zhang Y, Yeung M et al. Minocycline reduces gadolinium-enhancing magnetic resonance imaging lesions in multiple sclerosis. Ann. Neurol. 55(5), 756 (2004).
-
(2004)
Ann. Neurol.
, vol.55
, Issue.5
, pp. 756
-
-
Metz, L.M.1
Zhang, Y.2
Yeung, M.3
-
82
-
-
72449159325
-
Glatiramer acetate in combination with minocycline in patients with relapsing-remitting multiple sclerosis: Results of a Canadian, multicenter, double-blind, placebo-controlled trial
-
Metz LM, Li D, Traboulsee A et al. Glatiramer acetate in combination with minocycline in patients with relapsing-remitting multiple sclerosis: results of a Canadian, multicenter, double-blind, placebo-controlled trial. Mult. Scler. 15(10), 1183-1194 (2009).
-
(2009)
Mult. Scler.
, vol.15
, Issue.10
, pp. 1183-1194
-
-
Metz, L.M.1
Li, D.2
Traboulsee, A.3
-
83
-
-
0037044284
-
Statins as immunomodulators: Comparison with interferon-b 1b in MS
-
Neuhaus O, Strasser-Fuchs S, Fazekas F et al. Statins as immunomodulators: comparison with interferon-b 1b in MS. Neurology 59(7), 990-997 (2002).
-
(2002)
Neurology
, vol.59
, Issue.7
, pp. 990-997
-
-
Neuhaus, O.1
Strasser-Fuchs, S.2
Fazekas, F.3
-
84
-
-
0037038402
-
The HMG-CoA reductase inhibitor, atorvastatin, promotes a Th2 bias and reverses paralysis in central nervous system autoimmune disease
-
Youssef S, Stüve O, Patarroyo JC et al. The HMG-CoA reductase inhibitor, atorvastatin, promotes a Th2 bias and reverses paralysis in central nervous system autoimmune disease. Nature 420(6911), 78-84 (2002).
-
(2002)
Nature
, vol.420
, Issue.6911
, pp. 78-84
-
-
Youssef, S.1
Stüve, O.2
Patarroyo, J.C.3
-
85
-
-
2442561768
-
Oral simvastatin treatment in relapsing-remitting multiple sclerosis
-
DOI 10.1016/S0140-6736(04)16205-3, PII S0140673604162053
-
Vollmer T, Key L, Durkalski V et al. Oral simvastatin treatment in relapsing-remitting multiple sclerosis. Lancet 363, 1607-1608 (2004). (Pubitemid 38625664)
-
(2004)
Lancet
, vol.363
, Issue.9421
, pp. 1607-1608
-
-
Vollmer, T.1
Key, L.2
Durkalski, V.3
Tyor, W.4
Corboy, J.5
Markovic-Plese, S.6
Preiningerova, J.7
Rizzo, M.8
Singh, I.9
-
86
-
-
44849127754
-
Oral high dose atrvastatin treatment in relapsing-remitting multiple sclerosis
-
Paul F, Waiczies S, Wuerfel J et al. Oral high dose atrvastatin treatment in relapsing-remitting multiple sclerosis. PLoS One 3(4), e1928 (2008).
-
(2008)
PLoS One
, vol.3
, Issue.4
-
-
Paul, F.1
Waiczies, S.2
Wuerfel, J.3
-
87
-
-
56549086423
-
Combining b interferon and atorvastatin may increase disease activity in multiple sclerosis
-
Birnbaum G, Cree B, Altafullah I, Zinser M, Reder AT. Combining b interferon and atorvastatin may increase disease activity in multiple sclerosis. Neurology 71(18), 1390-1395 (2008).
-
(2008)
Neurology
, vol.71
, Issue.18
, pp. 1390-1395
-
-
Birnbaum, G.1
Cree, B.2
Altafullah, I.3
Zinser, M.4
Reder, A.T.5
-
88
-
-
0024204319
-
Remission induction in non-Hodgkin lymphoma with reshaped human monoclonal antibody CAMPATH-1H
-
Hale G, Dyer MJ, Clark MR et al. Remission induction in non-Hodgkin lymphoma with reshaped human monoclonal antibody CAMPATH-1H. Lancet 2(8625), 1394-1399 (1988).
-
(1988)
Lancet
, vol.2
, Issue.8625
, pp. 1394-1399
-
-
Hale, G.1
Dyer, M.J.2
Clark, M.R.3
-
89
-
-
0025068211
-
Purging in auto-and allografts: Monoclonal antibodies which use human complement and other natural effector mechanisms
-
discussion 152-154
-
Cobbold SP, Hale G, Clark MR, Waldmann H. Purging in auto-and allografts: monoclonal antibodies which use human complement and other natural effector mechanisms. Prog. Clin. Biol. Res. 333, 139-151; discussion 152-154 (1990).
-
(1990)
Prog. Clin. Biol. Res.
, vol.333
, pp. 139-151
-
-
Cobbold, S.P.1
Hale, G.2
Clark, M.R.3
Waldmann, H.4
-
90
-
-
31544467633
-
The window of therapeutic opportunity in multiple sclerosis: Evidence from monoclonal antibody therapy
-
Coles AJ, Cox A, Le Page E et al. The window of therapeutic opportunity in multiple sclerosis: evidence from monoclonal antibody therapy. J. Neurol. 253(1), 98-108 (2006).
-
(2006)
J. Neurol.
, vol.253
, Issue.1
, pp. 98-108
-
-
Coles, A.J.1
Cox, A.2
Le Page, E.3
-
91
-
-
54949143968
-
Alemtuzumab vs. interferon b-1a in early multiple sclerosis
-
Coles AJ, Compston DA, Selmaj KW et al. Alemtuzumab vs. interferon b-1a in early multiple sclerosis. N. Engl. J. Med. 359(17), 1786-1801 (2008).
-
(2008)
N. Engl. J. Med.
, vol.359
, Issue.17
, pp. 1786-1801
-
-
Coles, A.J.1
Compston, D.A.2
Selmaj, K.W.3
-
92
-
-
1842368507
-
IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma
-
Maloney DG, Grillo-López AJ, White CA et al. IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma. Blood 90(6), 2188-2195 (1997).
-
(1997)
Blood
, vol.90
, Issue.6
, pp. 2188-2195
-
-
Maloney, D.G.1
Grillo-López, A.J.2
White, C.A.3
-
93
-
-
39049115197
-
The B cell-old player, new position on the team
-
McFarland HF. The B cell-old player, new position on the team. N. Engl. J. Med. 358(7), 664-665 (2008).
-
(2008)
N. Engl. J. Med.
, vol.358
, Issue.7
, pp. 664-665
-
-
McFarland, H.F.1
-
94
-
-
33751085414
-
Rituximab reduces B cells and T cells in cerebrospinal fuid of multiple sclerosis patients
-
Cross AH, Stark JL, Lauber J, Ramsbottom MJ, Lyons JA. Rituximab reduces B cells and T cells in cerebrospinal fuid of multiple sclerosis patients. J. Neuroimmunol. 180, 63-70 (2006).
-
(2006)
J. Neuroimmunol.
, vol.180
, pp. 63-70
-
-
Cross, A.H.1
Stark, J.L.2
Lauber, J.3
Ramsbottom, M.J.4
Lyons, J.A.5
-
95
-
-
39049142995
-
B-cell depletion with rituximab in relapsing-remitting multiple sclerosis
-
DOI 10.1056/NEJMoa0706383
-
Hauser SL, Waubant E, Arnold DL et al. B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. N. Engl. J. Med. 358(7), 676-688 (2008). (Pubitemid 351240747)
-
(2008)
New England Journal of Medicine
, vol.358
, Issue.7
, pp. 676-688
-
-
Hauser, S.L.1
Waubant, E.2
Arnold, D.L.3
Vollmer, T.4
Antel, J.5
Fox, R.J.6
Bar-Or, A.7
Panzara, M.8
Sarkar, N.9
Agarwal, S.10
Langer-Gould, A.11
Smith, C.H.12
-
96
-
-
37149023520
-
Humanized anti-CD25 antibody treatment with daclizumab in multiple sclerosis
-
Martin R. Humanized anti-CD25 antibody treatment with daclizumab in multiple sclerosis. Neurodegener. Dis. 5(1), 23-26 (2008).
-
(2008)
Neurodegener. Dis.
, vol.5
, Issue.1
, pp. 23-26
-
-
Martin, R.1
-
97
-
-
33645812129
-
Regulatory CD56(bright) natural killer cells mediate immunomodulatory effects of IL-2Ra-targeted therapy (daclizumab) in multiple sclerosis
-
Bielekova B, Catalfamo M, Reichert-Scrivner S et al. Regulatory CD56(bright) natural killer cells mediate immunomodulatory effects of IL-2Ra-targeted therapy (daclizumab) in multiple sclerosis. Proc. Natl Acad. Sci. USA 103(15), 5941-5946 (2006).
-
(2006)
Proc. Natl Acad. Sci. USA
, vol.103
, Issue.15
, pp. 5941-5946
-
-
Bielekova, B.1
Catalfamo, M.2
Reichert-Scrivner, S.3
-
98
-
-
64549095397
-
A Phase 2 randomized double-blind placebo-controlled, multicenter study of subcutaneous daclizumab, a humanized anti-CD-25 monoclonal antibody in patients with active relapsing forms of multiple sclerosis: Week 44 results
-
Kaufman MD, Wynn DR, Montalban X. A Phase 2 randomized double-blind placebo-controlled, multicenter study of subcutaneous daclizumab, a humanized anti-CD-25 monoclonal antibody in patients with active relapsing forms of multiple sclerosis: week 44 results. Neurology 70(Suppl. 1), A220 (2008).
-
(2008)
Neurology
, vol.70
, Issue.SUPPL. 1
-
-
Kaufman, M.D.1
Wynn, D.R.2
Montalban, X.3
-
99
-
-
77950850216
-
New approaches in the management of spasticity in multiple sclerosis patients: Role of cannabinoids
-
Smith PF. New approaches in the management of spasticity in multiple sclerosis patients: role of cannabinoids. Ther. Clin. Risk Manag. 6, 59-63 (1020).
-
(1020)
Ther. Clin. Risk Manag.
, vol.6
, pp. 59-63
-
-
Smith, P.F.1
-
100
-
-
67651171245
-
The endocannabinoid anandamide from immunomodulation to neuroprotection. Implications for multiple sclerosis
-
Correa FG, Mestre L, Docagne F, Borreli J, Guaza C. The endocannabinoid anandamide from immunomodulation to neuroprotection. Implications for multiple sclerosis. Vitam. Hom. 81, 207-225 (2009).
-
(2009)
Vitam. Hom.
, vol.81
, pp. 207-225
-
-
Correa, F.G.1
Mestre, L.2
Docagne, F.3
Borreli, J.4
Guaza, C.5
-
101
-
-
52949104790
-
The endocannabinoid system and multiple sclerosis
-
Baker D, Pryce G. The endocannabinoid system and multiple sclerosis. Curr. Pharm. Des. 14(23), 2326-2336 (2008).
-
(2008)
Curr. Pharm. Des.
, vol.14
, Issue.23
, pp. 2326-2336
-
-
Baker, D.1
Pryce, G.2
-
102
-
-
41749084838
-
Cannabinoids and neuroprotection in motor-related disorders
-
De Lago E, Fernandez-Ruiz J. Cannabinoids and neuroprotection in motor-related disorders. CNS Neurol. Disord. Drug Targets 6(6), 377-387 (2007).
-
(2007)
CNS Neurol. Disord. Drug Targets
, vol.6
, Issue.6
, pp. 377-387
-
-
De Lago, E.1
Fernandez-Ruiz, J.2
-
103
-
-
77952493930
-
Anandamide suppresses proliferation and cytokine release from primary human T-lymphocytes mainly via CB2 receptors
-
Cencioni MT, Chiurchiù V, Catanzaro G et al. Anandamide suppresses proliferation and cytokine release from primary human T-lymphocytes mainly via CB2 receptors. PloS One 5, 1-10 (2010).
-
(2010)
PloS One
, vol.5
, pp. 1-10
-
-
Cencioni, M.T.1
Chiurchiù, V.2
Catanzaro, G.3
-
104
-
-
28744438738
-
Antigen-specifc therapies in multiple sclerosis
-
Sospedra M, Martin R. Antigen-specifc therapies in multiple sclerosis. Int. Rev. Immunol. 24, 393-413 (2005).
-
(2005)
Int. Rev. Immunol.
, vol.24
, pp. 393-413
-
-
Sospedra, M.1
Martin, R.2
-
105
-
-
0027467440
-
Double-blind pilot trial of oral tolerization with myelin antigens in multiple sclerosis
-
Weiner HL, Mackin GA, Matsui M et al. Double-blind pilot trial of oral tolerization with myelin antigens in multiple sclerosis. Science 259, 1321-1324 (1993).
-
(1993)
Science
, vol.259
, pp. 1321-1324
-
-
Weiner, H.L.1
MacKin, G.A.2
Matsui, M.3
-
106
-
-
0000131029
-
Clinical results of Phase III trial in of oral myelin in relapsing remitting multiple sclerosis
-
Oral myelin Group
-
Panitch H, Hrancic G, Oral myelin Group. Clinical results of Phase III trial in of oral myelin in relapsing remitting multiple sclerosis. Ann. Neurol. 42, 467 (1997).
-
(1997)
Ann. Neurol.
, vol.42
, pp. 467
-
-
Panitch, H.1
Hrancic, G.2
-
107
-
-
33746446276
-
Intravenous synthetic peptide MBP8298 delayed disease progression in an HLA Class II-defned cohort of patients with progressive multiple sclerosis: Results of a 24-month double-blind placebo-controlled clinical trial and 5 years of follow-up treatment
-
Warren KG, Catz I, Ferenczi LZ, Krantz MJ. Intravenous synthetic peptide MBP8298 delayed disease progression in an HLA Class II-defned cohort of patients with progressive multiple sclerosis: results of a 24-month double-blind placebo-controlled clinical trial and 5 years of follow-up treatment. Eur. J. Neurol. 13(8), 887-895 (2006).
-
(2006)
Eur. J. Neurol.
, vol.13
, Issue.8
, pp. 887-895
-
-
Warren, K.G.1
Catz, I.2
Ferenczi, L.Z.3
Krantz, M.J.4
-
108
-
-
39349098254
-
Vaccines for multiple sclerosis: Progress to date
-
Correale J, Farez M, Gilmore W. Vaccines for multiple sclerosis: progress to date. CNS Drugs 22(3), 175-198 (2008).
-
(2008)
CNS Drugs
, vol.22
, Issue.3
, pp. 175-198
-
-
Correale, J.1
Farez, M.2
Gilmore, W.3
-
109
-
-
0033791462
-
Induction of a non-encephalitogenic type 2 T helper-cell autoimmune response in multiple sclerosis after administration of an altered peptide ligand in a placebo-controlled, randomized Phase II trial
-
The Altered Peptide Ligand in Relapsing MS Study Group
-
Kappos L, Comi G, Panitch H. Induction of a non-encephalitogenic type 2 T helper-cell autoimmune response in multiple sclerosis after administration of an altered peptide ligand in a placebo-controlled, randomized Phase II trial. The Altered Peptide Ligand in Relapsing MS Study Group. Nat. Med. 6(10), 1176-1182 (2000).
-
(2000)
Nat. Med.
, vol.6
, Issue.10
, pp. 1176-1182
-
-
Kappos, L.1
Comi, G.2
Panitch, H.3
-
110
-
-
0019487117
-
Vaccination against autoimmune encephalomyelitis with T-lymphocyte line cells reactive against myelin basic protein
-
Ben-Nun A, Wekerle H, Cohen IR. Vaccination against autoimmune encephalomyelitis with T-lymphocyte line cells reactive against myelin basic protein. Nature 292, 60-61 (1981).
-
(1981)
Nature
, vol.292
, pp. 60-61
-
-
Ben-Nun, A.1
Wekerle, H.2
Cohen, I.R.3
-
111
-
-
69949145977
-
Antigen-specifc therapies in multiple sclerosis
-
Giacomini PS, Bar-Or A. Antigen-specifc therapies in multiple sclerosis. Expert Opin. Emerg. Drugs 14(3), 551-560 (2009).
-
(2009)
Expert Opin. Emerg. Drugs
, vol.14
, Issue.3
, pp. 551-560
-
-
Giacomini, P.S.1
Bar-Or, A.2
-
112
-
-
84979726329
-
Injection of adult neurospheres induces recovery in a chronic model of multiple sclerosis
-
Pluchino S, Quattrini A, Brambilla E et al. Injection of adult neurospheres induces recovery in a chronic model of multiple sclerosis. Nature 422(6933), 688-694 (2003).
-
(2003)
Nature
, vol.422
, Issue.6933
, pp. 688-694
-
-
Pluchino, S.1
Quattrini, A.2
Brambilla, E.3
-
113
-
-
33244487404
-
Transplanted neural precursor cells reduce brain infammation to attenuate chronic experimental autoimmune encephalomyelitis
-
Einstein O, Grigoriadis N, Mizrachi-Kol R et al. Transplanted neural precursor cells reduce brain infammation to attenuate chronic experimental autoimmune encephalomyelitis. Exp. Neurol. 198(2), 275-284 (2006).
-
(2006)
Exp. Neurol.
, vol.198
, Issue.2
, pp. 275-284
-
-
Einstein, O.1
Grigoriadis, N.2
Mizrachi-Kol, R.3
-
114
-
-
38049086826
-
Immunomodulation and neuroprotection with mesenchymal bone marrow stem cells (MSCs): Aproposed treatment for multiple sclerosis and other neuroimmunological neurodegenerative diseases
-
Karussis D, Kassis I, Kurkalli B, Slavin S. Immunomodulation and neuroprotection with mesenchymal bone marrow stem cells (MSCs): Aproposed treatment for multiple sclerosis and other neuroimmunological neurodegenerative diseases. J. Neurol. Sci. 265, 131-135 (2008).
-
(2008)
J. Neurol. Sci.
, vol.265
, pp. 131-135
-
-
Karussis, D.1
Kassis, I.2
Kurkalli, B.3
Slavin, S.4
-
115
-
-
77951926479
-
The therapeutic potential of mesenchymal stem cell transplantation as a treatment for multiple sclerosis: Consensus report of the International MSCT Study Group
-
Freedman MS, Bar-Or A, Atkins HL et al. The therapeutic potential of mesenchymal stem cell transplantation as a treatment for multiple sclerosis: consensus report of the International MSCT Study Group. Mult. Scler. 16(4), 503-510 (2010).
-
(2010)
Mult. Scler.
, vol.16
, Issue.4
, pp. 503-510
-
-
Freedman, M.S.1
Bar-Or, A.2
Atkins, H.L.3
-
116
-
-
2342639578
-
Mechanisms of and perspectives on the mesenchymal stem cell in immunotherapy
-
Zhao RC, Liao L, Han Q. Mechanisms of and perspectives on the mesenchymal stem cell in immunotherapy. J. Lab. Clin. Med. 143(5), 284-291 (2004).
-
(2004)
J. Lab. Clin. Med.
, vol.143
, Issue.5
, pp. 284-291
-
-
Zhao, R.C.1
Liao, L.2
Han, Q.3
-
117
-
-
49949093283
-
Autologous haematopoietic stem-cell transplantation in multiple sclerosis
-
Mancardi G, Saccardi R. Autologous haematopoietic stem-cell transplantation in multiple sclerosis. Lancet Neurol. 7(7), 626-636 (2008).
-
(2008)
Lancet Neurol.
, vol.7
, Issue.7
, pp. 626-636
-
-
Mancardi, G.1
Saccardi, R.2
-
118
-
-
72949084345
-
Autologous hemapoietic stem cell transplantation for multiple sclerosis: Is it worthwhile?
-
Fassas A, Mancardi GL. Autologous hemapoietic stem cell transplantation for multiple sclerosis: Is it worthwhile? Autoimmunity 28, 1 (2008).
-
(2008)
Autoimmunity
, vol.28
, pp. 1
-
-
Fassas, A.1
Mancardi, G.L.2
-
119
-
-
59349089705
-
Early highly aggressive MS successfully treated by heamatopoietic stem cell transplantation
-
Fagius J, Lundgren J, Oberg G. Early highly aggressive MS successfully treated by heamatopoietic stem cell transplantation. Mult. Scler. 15(2), 229-237 (2009).
-
(2009)
Mult. Scler.
, vol.15
, Issue.2
, pp. 229-237
-
-
Fagius, J.1
Lundgren, J.2
Oberg, G.3
-
120
-
-
0036151857
-
Neuroprotection and neurodegenerative disease
-
Vajda FJE. Neuroprotection and neurodegenerative disease. J. Clin. Neurosci. 9(1), 4-8 (2002).
-
(2002)
J. Clin. Neurosci.
, vol.9
, Issue.1
, pp. 4-8
-
-
Fje, V.1
-
121
-
-
70350551949
-
Linkage between immunomodulation neuroprotection and neurogeneisis
-
Aharoni R, Arnon R. Linkage between immunomodulation neuroprotection and neurogeneisis. Drug News Perspect. 22(6), 301-313 (2009).
-
(2009)
Drug News Perspect.
, vol.22
, Issue.6
, pp. 301-313
-
-
Aharoni, R.1
Arnon, R.2
-
122
-
-
77649290565
-
Neuroprotection, regeneration and immunomodulation: Broadening the therapeutic repertoire in multiple sclerosis
-
Aktas O, Kieseier B, Hartung AP. Neuroprotection, regeneration and immunomodulation: broadening the therapeutic repertoire in multiple sclerosis. Trends in Neurosci. 33(3), 145-152 (2010).
-
(2010)
Trends in Neurosci.
, vol.33
, Issue.3
, pp. 145-152
-
-
Aktas, O.1
Kieseier, B.2
Hartung, A.P.3
-
123
-
-
77949634115
-
Dalfampridine approved for MS
-
Traynor K. Dalfampridine approved for MS. Am. J. Health Sys. Pharm. 67(5), 335 (2010).
-
(2010)
Am. J. Health Sys. Pharm.
, vol.67
, Issue.5
, pp. 335
-
-
Traynor, K.1
-
124
-
-
16844385713
-
Interferon p promotes nerve growth factor secretion early in the course of multiple sclerosis
-
Biernacki K, Antel JP, Blain M et al. Interferon p promotes nerve growth factor secretion early in the course of multiple sclerosis. Arch. Neurol. 62(4), 563-568 (2005).
-
(2005)
Arch. Neurol.
, vol.62
, Issue.4
, pp. 563-568
-
-
Biernacki, K.1
Antel, J.P.2
Blain, M.3
-
125
-
-
0032525977
-
Interferon-p inhibits mitogen induced astrocyte proliferation in vitro
-
Malik O, Compston DA, Scolding NJ. Interferon-p inhibits mitogen induced astrocyte proliferation in vitro. J. Neuroimmunol. 86(2), 155-162 (1998).
-
(1998)
J. Neuroimmunol.
, vol.86
, Issue.2
, pp. 155-162
-
-
Malik, O.1
Compston, D.A.2
Scolding, N.J.3
-
126
-
-
33751540077
-
Interferon-p and neuroprotection in multiple sclerosis-facts, hopes and phantasies
-
Kieseier BC, Hartung HP. Interferon-p and neuroprotection in multiple sclerosis-facts, hopes and phantasies. Exp. Neurol 10, 1-4 (2007).
-
(2007)
Exp. Neurol
, vol.10
, pp. 1-4
-
-
Kieseier, B.C.1
Hartung, H.P.2
-
127
-
-
33747371157
-
Effects of interferon-b-1a on neuronal survival under autoimmune infammatory conditions
-
Sättler MB, Demmer I, Williams SK et al. Effects of interferon-b-1a on neuronal survival under autoimmune infammatory conditions. Exp. Neurol. 201(1), 172-181 (2006).
-
(2006)
Exp. Neurol.
, vol.201
, Issue.1
, pp. 172-181
-
-
Sättler, M.B.1
Demmer, I.2
Williams, S.K.3
-
128
-
-
0033544320
-
Use of the brain parenchymal fraction to measure whole brain atrophy in relapsing-remitting MS
-
Multiple Sclerosis Collaborative Research Group
-
Rudick RA, Fisher E, Lee JC, Simon J, Jacobs L. Use of the brain parenchymal fraction to measure whole brain atrophy in relapsing-remitting MS. Multiple Sclerosis Collaborative Research Group. Neurology 53(8), 1698-1704 (1999).
-
(1999)
Neurology
, vol.53
, Issue.8
, pp. 1698-1704
-
-
Rudick, R.A.1
Fisher, E.2
Lee, J.C.3
Simon, J.4
Jacobs, L.5
-
129
-
-
0035788425
-
Axonal metabolic recovery in multiple sclerosis patients treated with interferon b-1b
-
Narayanan S, De Stefano N, Francis GS et al. Axonal metabolic recovery in multiple sclerosis patients treated with interferon b-1b. J. Neurol. 248(11), 979-986 (2001).
-
(2001)
J. Neurol.
, vol.248
, Issue.11
, pp. 979-986
-
-
Narayanan, S.1
De Stefano, N.2
Francis, G.S.3
-
130
-
-
0037783991
-
MRI brain T1 relaxation time changes in MS patients increase over time in both the white matter and the cortex
-
Parry A, Clare S, Jenkinson M, Smith S, Palace J. Matthews PM. MRI brain T1 relaxation time changes in MS patients increase over time in both the white matter and the cortex. J. Neuroimaging 13(3), 234-239 (2003).
-
(2003)
J. Neuroimaging
, vol.13
, Issue.3
, pp. 234-239
-
-
Parry, A.1
Clare, S.2
Jenkinson, M.3
Smith, S.4
Palace, J.5
Matthews, P.M.6
-
131
-
-
30044451754
-
The immunomodulator glatiramer acetate augments the expression of neurotrophic factors in brains of experimental autoimmune encephalomyelitis mice
-
Aharoni R, Eylam R, Domev H, Labunsky G, Sela M, Arnon R. The immunomodulator glatiramer acetate augments the expression of neurotrophic factors in brains of experimental autoimmune encephalomyelitis mice. Proc. Natl Acad. Sci. USA 102, 19045-19050 (2005).
-
(2005)
Proc. Natl Acad. Sci. USA
, vol.102
, pp. 19045-19050
-
-
Aharoni, R.1
Eylam, R.2
Domev, H.3
Labunsky, G.4
Sela, M.5
Arnon, R.6
-
132
-
-
24144469398
-
Lower brain-derived neurotrophic factor in serum of relapsing remitting MS: Reversal by glatiramer acetate
-
Azoulay D, Vachapova V, Shihman B, Miler A, Karni A. Lower brain-derived neurotrophic factor in serum of relapsing remitting MS: reversal by glatiramer acetate. J. Neuroimmunol. 167, 215-218 (2005).
-
(2005)
J. Neuroimmunol.
, vol.167
, pp. 215-218
-
-
Azoulay, D.1
Vachapova, V.2
Shihman, B.3
Miler, A.4
Karni, A.5
-
133
-
-
33751536381
-
Effects of glatiramer acetate and interferon-b on neurodegeneration in a model of multiple sclerosis: A comparative study
-
Maier K, Kuhnert AV, Taheri N et al. Effects of glatiramer acetate and interferon-b on neurodegeneration in a model of multiple sclerosis: a comparative study. Am. J. Pathol. 169(4), 1353-1364 (2006).
-
(2006)
Am. J. Pathol.
, vol.169
, Issue.4
, pp. 1353-1364
-
-
Maier, K.1
Kuhnert, A.V.2
Taheri, N.3
-
134
-
-
24744435759
-
Neurogenesis and neuroprotection induced by peripheral immunomodulatory treatment of experimental autoimmune encephalomyelitis
-
Aharoni R, Arnon R, Eilam R. Neurogenesis and neuroprotection induced by peripheral immunomodulatory treatment of experimental autoimmune encephalomyelitis. J. Neuroscience 25(36), 8217-8228 (2005).
-
(2005)
J. Neuroscience
, vol.25
, Issue.36
, pp. 8217-8228
-
-
Aharoni, R.1
Arnon, R.2
Eilam, R.3
-
135
-
-
49649090657
-
Demyelination arrest and remyelination induced by glatiramer acetate treatment of experimental autoimmune encephalomyelitis
-
Aharoni R, Herschkovitz A, Eilam R. et al. Demyelination arrest and remyelination induced by glatiramer acetate treatment of experimental autoimmune encephalomyelitis. Proc. Natl Acad. Sci. USA 105(32), 11358-11363 (2008).
-
(2008)
Proc. Natl Acad. Sci. USA
, vol.105
, Issue.32
, pp. 11358-11363
-
-
Aharoni, R.1
Herschkovitz, A.2
Eilam, R.3
-
136
-
-
0035964157
-
Glatiramer Acetate reduces the proportion of new MS lesions evolving into 'black holes'
-
Filippi M, Rovaris M, Rocca MA. Glatiramer Acetate reduces the proportion of new MS lesions evolving into 'black holes'. Neurology 57, 731-733 (2001).
-
(2001)
Neurology
, vol.57
, pp. 731-733
-
-
Filippi, M.1
Rovaris, M.2
Rocca, M.A.3
-
137
-
-
28044444326
-
Axonal metabolic recovery and potential neuroprotective effect of glatiramer acetate in relapsing-remitting multiple sclerosis
-
Khan O, Shen Y, Caon C et al. Axonal metabolic recovery and potential neuroprotective effect of glatiramer acetate in relapsing-remitting multiple sclerosis. Mult. Scler. 11, 646-651 (2005).
-
(2005)
Mult. Scler.
, vol.11
, pp. 646-651
-
-
Khan, O.1
Shen, Y.2
Caon, C.3
-
138
-
-
40849089388
-
Therapeutic potential of statins in multiple sclerosis: Immune modulation, neuroprotection and neurorepair
-
Markovic-Plese S, Singh AK, Singh I. Therapeutic potential of statins in multiple sclerosis: immune modulation, neuroprotection and neurorepair. Future Neurol. 3(2), 153-167 (2008).
-
(2008)
Future Neurol.
, vol.3
, Issue.2
, pp. 153-167
-
-
Markovic-Plese, S.1
Singh, A.K.2
Singh, I.3
-
139
-
-
60549097585
-
Combination therapy of lovastatin and rolipram provides neuroprotection and promotes neurorepair in infammatory demyelination model of multiple sclerosis
-
Paintlia AS, Paintlia MK, Singh I, Skoff RB, Singh AK. Combination therapy of lovastatin and rolipram provides neuroprotection and promotes neurorepair in infammatory demyelination model of multiple sclerosis. Glia 57(2), 182-193 (2009).
-
(2009)
Glia
, vol.57
, Issue.2
, pp. 182-193
-
-
Paintlia, A.S.1
Paintlia, M.K.2
Singh, I.3
Skoff, R.B.4
Singh, A.K.5
-
140
-
-
49149097118
-
Neurotherapeutics in multiple sclerosis: Novel agents and emerging treatment strategies
-
DeAngelis T, Lublin F. Neurotherapeutics in multiple sclerosis: novel agents and emerging treatment strategies. Mt Sinai J. Med. 75(2), 157-167 (2008).
-
(2008)
Mt Sinai J. Med.
, vol.75
, Issue.2
, pp. 157-167
-
-
De Angelis, T.1
Lublin, F.2
-
141
-
-
38449111946
-
List of drugs in development for neurodegenerative diseases
-
Pogacic V, Herrling P. List of drugs in development for neurodegenerative diseases. Neurodegener. Dis. 4, 443-486 (2007).
-
(2007)
Neurodegener. Dis.
, vol.4
, pp. 443-486
-
-
Pogacic, V.1
Herrling, P.2
|